The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model

Acta Oncologica

Volumn 47, Issue 6, 2008, Pages 1009-1017

  Borg, Sixten ^a   Glenngård, Anna H ^a   Österborg, Anders ^b   Persson, Ulf ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA, HYPOCHROMIC; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 51149118894     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701744498     Document Type: Article

References (20)

1. Groopman JE, Itri LM. Chemotherapy-induced anaemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
2. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Anaemia Cancer Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004:2293-306.
3. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 2004;116(Suppl.7A):11S- 26S.
4. Couture F, Turner AR, Melosky B, Xiu L, Plante RK, Lau CY, et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005;10:63-71.
5. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70.
6. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20.
7. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
8. Remák E, Hutton J, Jones M, Zagari M. Changes in costeffectiveness over time - The case of Epoetin Alfa for renal replacement therapy patients in the UK. Eur J Health Econom 2003;4:115-21.
9. Rawlins MD, Culyer AJ. "National Institute for Health and Clinical Excellence and its value judgments". BMJ 2004;329(7459):224-7.
10. R Development Core Team (2006). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http:/www.R-project.org.
11. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-220.
12. Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S, et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response. Adv Ther 2005;22:208-24.
13. Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegard G, Johansson P, Jonsson B, et al. Erythropoietin therapy and cancer related anaemia: Updated Swedish recommendations. Med Oncol 2007;24:267-72.
14. Wilson J, Yao G, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epeotin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment, Available at URL=www.nice.org.uk, Accessed 22 September 2005.
15. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
16. The Swedish Association of the Pharmaceutical Industry (LIF), FASS, Pharmaceutical Specialities in Sweden. 2007, Linfo: Stockholm. Available at www.fass.se, accessed 17 January 2007.
17. Bartsch R, Wenzel C, Sevelda U, et al, Darbepoetin alpha as treatment for anemia in patients receiving chemo-therapy: A single-center experience. Anticancer Drugs 2005;16:617-20.
18. Heras P, Argyriou AA, Papapetropoulus S, et al. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients. Eur J Cancer Care (Engl) 2005;14:108-12.
19. The Southern Regional Health Care Board. Prices and reimbursements for the Southern Health Care Region, 2007, 2006-12-05, (In Swedish: Regionala Priser och Ersättningar 2002 för Södra Sjukvårdsregionen, Södra Regionvårdsnämnden). Available at www.srvn.org. Accessed 17 January 2007.
20. The Swedish National Board of Health and Welfare's guidelines for cardiac care 2004. Support for decisions in setting priorities [In Swedish]. Stockholm, Sweden: National Board of Health & Welfare; 2004.